Work

Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis

Year: 2017

Type: article

Study design: Clinical Trial

Source: Modern Rheumatology

DOI: 10.1080/14397595.2017.1337056

Authors: Yoshiya Tanaka, Tsutomu Takeuchi, Hisanori Umehara, Toshihiro Nanki, Nobuyuki Yasuda, Fumitoshi Tago, Makoto Kawakubo, Yasumi Kitahara, Seiichiro Hojo, Tetsu Kawano, Toshio Imai

Institutions: University of Occupational and Environmental Health Japan, Keio University, Nagahama City Hospital, Toho University, KAN Research Institute, Eisai (Japan)

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Novartis, AbbVie, Takeda Pharmaceutical Company, GlaxoSmithKline Japan, Daiichi-Sankyo, Eisai, Astellas Pharma, Taisho Toyama Pharmaceutical Company, Astellas Foundation for Research on Metabolic Disorders, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical

OpenAlex ID: W2730857027

FWCI: 7.461

Cites: 27

Cited by: 61

Related to: 10